Navigation Links
TGen and Washington University researchers discover new approach to treating endometrial cancer
Date:8/31/2008

, in cases where the tumors contained the altered FGFR2 gene. The altered gene causes the receptors to get stuck in the "on'' position and signal the endometrial cells to grow out of control.

"These findings could accelerate the development of new treatments for endometrial cancer because there are already drugs in clinical trials that inhibit FGFR2 function,'' Pollock said.

Current treatment of endometrial cancer can involve surgical removal of the uterus, radiation and chemotherapy. While many women are successfully treated with these approaches, about 15 percent of those with endometrioid endometrial cancer have persistent or recurring tumors that are resistant to current drug therapies. Mutations in several genes previously have been identified in endometrial tumors, but they have not been suitable drug targets until now.

"This targeted approach holds great promise for patients with uterine cancer (endometrioid endometrial) tumors that contain the FGFR2 mutation," said TGen physician-in-chief, Dr. Daniel Von Hoff, "and offers yet another powerful example of how genomic medicine is changing the way we look at and treat cancer."

Goodfellow agreed, "The discovery that endometrial cancer cells die when treated with an FGFR2 inhibitor - even when they carry other genetic abnormalities common in uterine cancers - suggests anti-FGFR2 therapies have great potential.''

The researchers' already established ties with the National Cancer Institute, which will assist with the clinical trials, should speed the development of new therapies, Goodfellow said. "Our collaborative group's strong ties with the NCI's Gynecologic Oncology Group will allow us to rapidly take our findings from the lab to patients.''

Endometrial cancer, which invades the inner wall of the uterus, is the most common gynecological cancer in the United States. This year more than 40,000 women will be diagnosed and nearly 7,500 women will die of the dis
'/>"/>

Contact: Galen Perry
gperry@tgen.org
602-343-8423
The Translational Genomics Research Institute
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. First IEEE-USA Innovation Forum coming to Washington area in November
2. DHS Begins Collecting 10 Fingerprints From International Visitors at Washington Dulles International Airport
3. Washington University, 2 industries, team to clean up mercury emissions
4. Missouri board grants Washington University Sustainability Center $3 million
5. Washington University increases fleet of Roche Genome Sequencer FLX Systems
6. Washington University unveils draft sequence of corn genome
7. 5th Annual World Health Care Congress April 21-23, Washington, D.C.
8. Analysis of Lake Washington microbes shows the power of metagenomic approaches
9. A study by the MUHC and McGill University opens a new door to understanding cancer
10. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
11. University of Oregon researcher finds that on waters surface, nitric acid is not so tough
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ... is accurate, flexible and robust – with the clinical ...
(Date:12/15/2014)... 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a ... recognition system measures the overall facial feature of ... and the distance between eyes. Facial recognition is ...
(Date:12/11/2014)...  That blood pressure plays a role in human health ... medical term for high blood pressure – was first described ... cuff that,s used in measuring blood pressure was invented in ... about hypertension, its triggers and its effects. In fact, recent ... the best ways to treat it. For example, ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... The sweetgum tree grows widely throughout the country and is ... "gumballs." Now, this spiny fruit may become an important source ... bird flu ?a drug that is currently in short supply ... of the sweetgum fruit contain significant amounts of shikimic acid, ...
... A pain–killing medication appears to halt the production of ... of breast cancer, a new study using tissue cultures ... experiments on breast cancer cells, scientists found that derivatives ... implicated in estrogen-dependent breast cancer. This form of breast ...
... to show that molecular variation in one gene may ... habitat. Research Professor Ilkka Hanski, University of Helsinki, and ... the population growth of the Glanville fritillary butterfly (Melitaea ... phosphoglucose isomerase (Pgi) enzyme. The result challenges previous views ...
Cached Biology News:Sweetgum tree could help lessen shortage of bird flu drug 2Pain killer fights breast cancer by targeting key enzyme 2Pain killer fights breast cancer by targeting key enzyme 3New discovery: Molecular variation in one gene affects the growth of natural populations 2
(Date:12/19/2014)... MA (PRWEB) December 18, 2014 iLab ... announced the appointment of Siri Bryant as the new ... new Director of Core Implementations. These two new leadership ... outstanding customer service by ensuring that iLab continues to ... “In the last four years, iLab has been deployed ...
(Date:12/19/2014)... BURLINGTON, Mass. , Dec. 18, 2014  Decision ... dental biomaterial market will grow moderately through ... implant procedures and growing awareness of dental biomaterials all ... underdeveloped markets such as China ... incomes will bring dental procedures within reach for a ...
(Date:12/17/2014)... (PRWEB) December 16, 2014 The ... since 2013, which is why IBISWorld updated its original ... continues to benefit from an intensified focus on environmental ... for new emission standards for power plants and a ... According to IBISWorld Industry Analyst Sarah Kahn, “a range ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
Breaking Biology Technology:iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... Sail graduate Darren Lynn Bousman, acclaimed Director of the ... its Full Sail Live facility on Monday, November 17, ... Repo! The Genetic Opera. The screening was followed by ... the university, and also featured actor and co-writer Terrance ...
... biotech firm and Laborium Biopharma, a subsidiary of Validapro Biosciences Inc. ... protein bioprocess production and scale-up. , ... Laval, Quebec ... firm and Laborium Biopharma, a subsidiary of Validapro Biosciences Inc. have ...
... ... St. Andrews by-the-Sea, ... https://www.atlanticabioenergy.com/ , NOTE TO EDITORS: Photo, video ... /PRNewswire/ - The global forestry industry is rapidly changing and it is incumbent on all stakeholders ...
Cached Biology Technology:Full Sail University Welcomed Back to Campus Graduate and Acclaimed Horror Director, Darren Lynn Bousman 2Full Sail University Welcomed Back to Campus Graduate and Acclaimed Horror Director, Darren Lynn Bousman 3Med Discovery and Laborium Biopharma Sign a Bioprocess Development Partnership Agreement 2Media Advisory - Atlantica BioEnergy Task Force Leaders' Roundtable 2
Immunogen: Synthetic peptide: N(171) H G F L S A D Q QL I K(183) Storage: -20 C, Avoid Freeze/Thaw Cycles...
The pCDF Expression System 1 plus Competent Cells contains 10 µg of pET-45b(+) DNA. pET-45b carries an N-terminal His•Tag ® coding sequence that is cleavable with enterokinase as well...
HIV-1 TAT (vN-21)...
Request Info...
Biology Products: